Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 136 in active class III/IV lupus nephritis
NL-OMON38318Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of siltuximab in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percent reduction from baseline in proteinuria at Week 24. Started Jun 2011; status: active, not recruiting.
02
Drugs
siltuximab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON38318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38318.